Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Top-line data expected in the first quarter of 2023 Data to be part of new drug application submission expected in third quarter of 2023 SAN JOSE, Calif. , Nov. 17, 2022 /PRNewswire/ -- MAPS...
The new chairman brings critical commercial expertise and pharmaceutical leadership needed during MAPS PBC's growth phase MDMA-assisted therapy, a novel treatment for posttraumatic stress disorder...
The FDA lifted the clinical hold from a MAPS-sponsored Phase 2 study of MDMA-assisted group therapy for the treatment of posttraumatic stress disorder among veterans at the VA Portland Health Care...
On PTSD Awareness Day, MAPS PBC announces plans to develop the New Drug Application for MDMA-assisted therapy in collaboration with MMS Holdings The second Phase 3 trial of the...
Experienced healthcare leaders bring decades of experience in global drug commercialization and patient access Appointment brings significant pharmaceutical leadership experience to the MAPS PBC board